Drug Profile

Lingdolinurad - Atom Therapeutics

Alternative Names: ABP-671

Latest Information Update: 12 Sep 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Atom Bioscience
Developer Atom Therapeutics
Class Antigouts; Antirheumatics; Small molecules; Uricosurics
Mechanism of Action SLC22A12 protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II/III Gout
Phase II Hyperuricaemia
Phase I Renal failure

Most Recent Events

09 Sep 2025 Efficacy and adverse events data from a phase II/III trial in Gout released by Atom Bioscience
03 Dec 2024 Atom Therapeutics and China Medical System Holdings enter into an exclusive commercialization agreement for Lingdolinurad in China, Hongkong and Macau
14 Nov 2024 Phase-I clinical trials in Renal failure (PO) Prior to November 2024

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com